DB
TBPH icon

Dmitry Balyasny’s Theravance Biopharma TBPH Stock Holding History

Dmitry Balyasny’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-20,098
Closed -$293K – 3541
2025
Q3 		$293K Buy
+20,098
New +$254K ﹤0.01% 2587
2024
Q3 		– Sell
-34,107
Closed -$289K – 3149
2024
Q2 		$289K Buy
34,107
+2,822
+9% +$25.5K ﹤0.01% 2239
2024
Q1 		$281K Buy
+31,285
New +$290K ﹤0.01% 2285
2023
Q4 		– Sell
-13,699
Closed -$118K – 2893
2023
Q3 		$118K Buy
+13,699
New +$132K ﹤0.01% 2109
2018
Q2 		– Sell
-65,149
Closed -$1.58M – 2134
2018
Q1 		$1.58M Sell
65,149
-23,543
-27% -$647K 0.01% 1063
2017
Q4 		$2.47M Sell
88,692
-91,908
-51% -$2.72M 0.01% 1080
2017
Q3 		$6.18M Buy
180,600
+24,850
+16% +$813K 0.02% 647
2017
Q2 		$6.21M Sell
155,750
-61,674
-28% -$2.37M 0.03% 695
2017
Q1 		$8.01M Buy
217,424
+35,059
+19% +$1.12M 0.04% 569
2016
Q4 		$5.81M Buy
+182,365
New +$5.66M 0.03% 650

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Dmitry Balyasny's TBPH Position: Q4 2025 in Review

Dmitry Balyasny sold out of Theravance Biopharma (TBPH) in Q4 2025, closing a stake of 20,098 shares — an estimated $293K sold.

Dmitry Balyasny first reported a position in TBPH in Q4 2016 and held it in 10 quarters. The position peaked at $8.01M in Q1 2017. 169 funds tracked by Wall St. Rank hold TBPH as of Q4 2025.

  • Dmitry Balyasny reported no remaining Theravance Biopharma position as of Q4 2025 after selling out during the quarter.
  • Dmitry Balyasny sold 20,098 Theravance Biopharma shares in Q4 2025, an estimated $293K.
  • Dmitry Balyasny first reported a position in Theravance Biopharma in Q4 2016 and held it in 10 quarters.
  • Dmitry Balyasny's Theravance Biopharma position peaked at $8.01M in Q1 2017.
  • 169 funds tracked by Wall St. Rank held Theravance Biopharma as of Q4 2025.

Based on Balyasny Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.